Companies
/Healthcare
Biomarin Pharmaceutical Inc
$60.59
▲ $2.08 (+3.56%) today
Markets open · 12:49pm ET
BioMarin (BMRN) Earnings History & Trends
57%
EPS beat rate
+42.06%
Avg. EPS surprise
Consecutive EPS beats
BMRN vs Market · 30-day return after each reportBMRNS&P 500
BMRN EPS Trend · estimate vs actualEstimateActual
BMRN Revenue Trend · estimate vs actualEstimateActual
How Often Does BioMarin Beat Earnings Estimates?
BioMarin beat EPS estimates in 4 of its last 7 reported quarters, and has beaten 2 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Non-GAAP EPS includes acquired IPR&D charges of $287.7 million (287,685 thousand) recorded in the quarter in connection with the Alesta Therapeutics acquisition; company expects Alesta and BMN 450 charges of approximately $320 million and $83 million for full-year 2026 (approximately $1.55 and $0.32 per share). GAAP diluted EPS of $(0.63) also reflects Amicus-related intangible amortization ($99 million), inventory step-up amortization ($18 million) and acquisition/restructuring costs ($47 million). | $0.23 est. $-0.11 | +304.81% | $1.0B est. $1.0B | +0.22% |
| Q2 2026 | $1.20 est. $0.95 | +25.76% | $989.7M est. $932.0M | +6.19% |
| Q1 2026 | $0.76 est. $0.91 | −16.86% | $766.2M est. $751.7M | +1.93% |
| Q4 2025 | $0.46 est. $0.56 | −17.95% | $874.6M est. $835.0M | +4.73% |
| Q3 2025 | $0.12 est. $0.32 | −62.50% | $776.1M est. $780.2M | −0.52% |
| Q2 2025 | $1.44 est. $1.01 | +42.31% | $825.4M est. $761.7M | +8.37% |
| Q1 2025 | $1.13 est. $0.95 | +18.87% | $745.1M est. $738.4M | +0.91% |
Figures from SEC filings and company reports. Not investment advice.